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Abstract: This study examined in detail patterns of cholinesterase
inhibitors (ChEIs) and memantine use and explored the relation-
ship between patient characteristics and such use. Patients with
probable Alzheimer disease AD (n=201) were recruited from the
Predictors Study in 3 academic AD centers and followed from early
disease stages for up to 6 years. Random effects logistic regressions
were used to examine effects of patient characteristics on ChEIs/
memantine use over time. Independent variables included measures
of function, cognition, comorbidities, the presence of extrapyr-
amidal signs, psychotic symptoms, age, sex, and patient’s living
situation at each interval. Control variables included assessment
interval, year of study entry, and site. During a 6-year study period,
rate of ChEIs use decreased (80.6% to 73.0%) whereas memantine
use increased (2.0% to 45.9%). Random effects logistic regression
analyses showed that ChEI use was associated with better function,
no psychotic symptoms, and younger age. Memantine use was
associated with better function, poorer cognition, living at home,
later assessment interval, and later year of study entry. Results
suggest that high rate of ChEI use and increasing memantine use
over time are consistent with current practice guidelines of
initiation of ChEIs in mild-to-moderate AD patients and initiation
of memantine in moderate-to-severe patients.
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Alzheimer disease (AD) is a degenerative disease of thebrain and is the leading cause of dementia in the elderly
individuals. Currently there is no cure for AD. Therapeutic
strategies aim at treating disease symptoms and delaying
the deterioration of cognition and daily functioning. Since
their introduction in 1997, cholinesterase inhibitors (ChEIs)
have been shown to temporarily stabilize or reduce the rate
of deterioration in measures of cognitive function, activities
of daily living, and behavior in some patients with mild-to-
moderate AD.1 Although there is controversy over whether
treatment results represent clinically important benefits,2
most AD clinical practice guidelines consider ChEIs to be
the first-line pharmacotherapy for mild-to-moderate AD.3
More recently, a N-methyl-D aspartate receptor antagonist,
memantine, was approved for moderate-to-severe demen-
tia.1,4 Patterns of using these antidementia treatments
recently began to be described in the literature, most
focusing on ChEIs.1,5–8
In addition to ChEIs and memantine, AD patients are
likely to be prescribed other medications, either to address
noncognitive symptoms of AD or to manage comorbidities.
Polypharmacy is common in elderly persons and has been
shown to be associated with adverse events such as increased
adverse drug interactions and increased medical care and
costs.9–11 AD patients are at high risks of polypharmacy
because of high rates of comorbidities.12 Although guidelines
have been developed to identify medications that are
inappropriate for use in the elderly,13 medication use in
AD patients has been described for few drug classes. Among
AD patients who were prescribed ChEIs, 17% to 35% have
been reported to use benzodiazepines, known to worsen
cognition, and 24% to 35% have been reported to use
anticholinergics that directly antagonize their effects.5–7,14
Most studies examining use of antidementia and
concomitant medications have been based on claims data
or data from clinical trials. Although claims data contain
detailed information on prescription medications, they
often lack clinical information. In contrast, although
clinical trials contain detailed clinical and prescription
information, patients included in clinical trials are followed
for only a short period of time and are often different from
those seen in real-world practices and limits the general-
izability of study results.15,16
This study uses data from the Predictors Study,
a large, multicenter cohort of patients with probable
AD, followed from early disease stages for up to 6 yearsCopyright r 2010 by Lippincott Williams & Wilkins
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to examine (1) patterns of ChEIs/memantine use, (2)
relationship between patient characteristics and ChEIs/
memantine use, and (3) patterns of concomitant medication
use. Our study design allows for substantially longer-term
analysis than can generally be conducted in clinical trials.
Substantial clinical information included in the Predictors
Study allows for more detailed examination of the relation-
ship between medication use and patient characteristics
than what would be possible with claims data.
METHODS
Sample
The sample was drawn from the Predictors 2 cohort,
consisting of patients recruited from Columbia University
Medical Center, Johns Hopkins School of Medicine, and
Massachusetts General Hospital. The study was approved
by each local Institutional Review Board. The inclusion/
exclusion criteria are fully described elsewhere.17–19 In
brief, the participants met DSM-III-R criteria for primary
degenerative dementia of the Alzheimer type and NINDS-
ADRDA criteria for probable AD. Enrollment required a
modified Mini-Mental State examination (mMMS) score
Z30, equivalent to approximately Z16 on the Folstein
Mini-Mental State Examination (MMSE).20,21 Clinical
diagnosis of AD has been confirmed in 93% of those with
postmortem evaluation,19 suggesting high degrees of
certainty in AD diagnosis.
Study recruitment began in 1997 and was staggered:
3% (n=6) entered the study in 1997, 8.5% (n=17) in 1998,
8.0% (n=16) in 1999, 26.9% (n=54) in 2000, 24.4%
(n=49) in 2001, 13.4% (n=27) in 2002, 10.0% (n=20) in
2003, and 6.0% (n=12) in 2004 or later. After the baseline
interview, patients were followed annually. Those who did
not respond at a particular visit could respond at a
subsequent visit. For data used in this analysis, 17 patients
had one assessment (8.5%), 41 had 2 (20.4%), 32 had 3
(15.9%), 36 had 4 (17.9%), 33 had 5 (16.4%), and 42 had 6
or more assessments (20.9%). Median follow-up for the
cohort was 4 years. Differences in the number of assess-
ments during follow-up reflect both continuous accrual of
patients and patient deaths (7%). Missed visits during
follow-up were rare: 15.6% missed 1 visit, 2.5% missed 2,
and 1% missed 3 visits. The analysis sample consisted of
785 observations from 201 patients.
Measures
Clinical Characteristics
Data on clinical characteristics of the patients were
recorded at each visit. Disease progression was characterized
by transition from milder stages of dementia to more severe
stages, measured by MMSE.20 Higher MMSE scores indi-
cate better cognition. Blessed Dementia Rating Scale
(BDRS) Parts I (Instrumental Activities of Daily Living)
and II (Basic Activities of Daily Living) were used to assess
patients’ functional capacity.22 Higher BDRS scores indicate
worse functioning. Columbia University Scale for Psycho-
pathology in AD (CUSPAD), a semi-structured interview
administered by physicians or trained research technicians,
was used to measure psychotic symptoms.23 We constructed
a dichotomous indicator for the presence of psychotic
symptoms if the patient had any delusions, hallucinations,
or illusions. A modified Unified Parkinson’s Disease Rating
Scale (UPDRS) was used to measure the presence of
extrapyramidal signs (EPS).24,25 We constructed a dichot-
omous indicator for the presence of EPS if any of the
following 11 items was rated 2 or higher (with 0 being
normal and 4 maximum impairment): speech, facial expres-
sion, tremor at rest, neck rigidity, right arm rigidity, left arm
rigidity, right leg rigidity, left leg rigidity, posture, gait, or
bradykinesia. Patients’ medical histories were used to
construct a modified Charlson comorbidity index.19,26
Sociodemographic Characteristics
At baseline, demographic characteristics (eg, age,
ethnicity, sex, education) were recorded. Information on
living arrangements was collected at each visit, dichoto-
mized as living at home or in a long-term care facility (ie,
retirement home, assisted living facility, or nursing home).
Use of ChEIs and Memantine
All patient/caregiver report of prescription and over the
counter (OTC) medications use were recorded at each visit on
a medication acquisition form. As the ChEIs have been shown
to have similar efficacy despite slightly different pharmaco-
logical properties, we constructed a dichotomous variable
indicating any ChEIs use, and a separate dichotomous
variable indicating memantine use. To examine concurrent
ChEIs/memantine use, we also constructed indicators for
using (1) ChEIs only, (2) memantine only, (3) both ChEIs and
memantine, or (4) neither ChEIs nor memantine. Although
tacrine is also approved by the FDA for mild-to-moderate
AD, it is rarely used owing to hepatoxicity. No patient in the
sample reported using tacrine.
Year of Study Entry
The ChEIs and memantine were approved by the FDA
for treatment of AD at different times. Specifically, among
ChEIs, donepezil was approved for treatment of mild-
to-moderate AD on November 25, 1996 (the label was
expanded to include severe AD in 2007), rivastigmine was
approved for treatment of mild-to-moderate AD on April
21, 2000, and galantamine was approved for treatment of
mild-to-moderate AD on February 28, 2001. More recently,
memantine was approved by the FDA for treatment of
moderate-to-severe AD on October 16, 2003. Year of study
entry was included to control for availability of medications
on the market.
Concomitant Medications Use
In addition to ChEIs and memantine, patients and
informants reported using a total of 429 unique prescrip-
tion medications and 176 OTC medications. A neurologist
who specializes in dementia (N.S.) categorized all prescrip-
tion medications into the following 18 categories: anti-
coagulants, antiplatelets, nonsteroidal antiinflamatory
drugs (NSAIDs), antihistamine, prostate-anticholinergic,
for dyslipidemia, antidiabetics, antihypertensives, antiepi-
leptics, antipsychotics, antiemetic neuroleptics, stimulants,
for Parkinson disease, antidepressants, benzodiazepines,
narcotics, hormones, and other prescription medications.
All OTC drugs were categorized as either vitamins or other.
For each drug category, we constructed a dichotomous
variable indicating whether a patient reported using any
medications in that drug category at each visit. A complete
list of medications by category is available upon request
from the investigators.
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Analysis
Random effects logistic regression models were used to
estimate the effects of patient characteristics on ChEIs/
memantine use over time.27 This framework allows an
exploration of the combination of fixed effects that are
common to all individuals in the population or common to
groups of individuals and random effects that indicate
individual-level variations. The fixed effects parameters are
interpreted as average effects of each explanatory variable
on the dependent variables. The random effects are inter-
preted as deviations from the mean for each individual, and
therefore model the magnitude of unobserved heterogeneity.
In this regression model, time was measured in years
following baseline (year 0). The coefficient on year estimates
average linear trend in ChEIs/memantine use over time. We
also included a year-squared term in the model to estimate
the rate of change over time. For example, an odds ratio of
>1 on the coefficient on time indicates increasing like-
lihood of use over time. An odds ratio >1 on the year-
squared term indicates that the rate of change estimated by
the linear term is accelerating over time.
All clinical variables were entered as time-variant
covariates except for Charlson comorbidity index because
there was little change in the measure over time. Demo-
graphic variables except living arrangement were entered as
time-invariant covariates. As the sample was overwhelmingly
white (93%), we did not include race as an expla-
natory variable.
We controlled for the effects of availability of
medications on the market by including year of study
entry. We also controlled for possible differences in use
patterns by region by including indicators for study sites.
All analyses were done using Stata 9.0.28
RESULTS
Baseline Characteristics
At baseline, patients’ average age was 76 (SD=8.1),
61% were female, 93% were white, and 84% lived at home
(Table 1, first column). Patients were highly educated, with
an average of 14 years of schooling (SD=3.1). Average
MMSE was 22.0 (SD=3.5) and average BDRS was 4.8
(SD=2.5). Psychotic symptoms (34%) and extrapyramidal
signs (16%) were common. On average, patients had 1.5
comorbidities (SD=1.1), with 15% with none, 43% with 1,
26% with 2, and 16% with 3 or more comorbidities.
Unadjusted Results on ChEIs and Memantine
Use Over Time
Figure 1 shows rates of ChEIs/memantine use over
time. At baseline, 80.6% of the patients used ChEIs; 2.0%
memantine. By year 6, the proportion of patients who used
ChEIs decreased to 73.0% (P=0.003); and the proportion
of patients who used memantine increased to 45.9%
(P<0.001). The proportion of patients who used specific
ChEIs remained relatively stable (all P>0.05), with an
average of 61.7% reported using donepezil, 4.8% rivastig-
mine, and 13.6% galantamine. Examination of concurrent
ChEIs/memantine use showed that, over time, whereas the
proportion of patients who used neither ChEIs nor
memantine remained relatively stable at approximately
20%, the proportion of patients who used ChEIs-only
decreased from 78.6% to 32.4%, those who used both
ChEIs and memantine increased from 2.0% to 40.5%, and
those who used memantine-only increased from 0% to
5.4%.
Multivariate Results on Relationship Between
Patient Characteristics and ChEIs and
Memantine Use
Table 1 also presents results of random effects logistic
regression models of the effects of patient characteristics on
ChEIs/memantine use. The second column of Table 1
shows that patients with worse functioning were less likely
to use ChEIs (OR=0.83, P<0.05), as were patients with
psychotic symptoms (OR=0.47, P<0.05) or those who
were older (OR=0.86, P<0.001). After controlling for year
of study entry, the probability of using ChEIs increased over
time (OR=1.29, P<0.05). The third column of Table 1
shows that patients with worse functioning were less likely to
TABLE 1. Baseline Characteristics and Random Effects Model of ChEIs and Memantine Use Over Time
Baseline Characteristics Mean (s.d) ChEIs OR (s.e.) Memantine OR (s.e.)
Functional capacity, BDRS 4.8 (2.5) 0.8337 (0.080)* 0.7134 (0.101)**
Folstein MMSE 22.0 (3.5) 1.0618 (0.045) 0.8062 (0.046)***
Extrapyramidal signs (%) 15.5 1.0463 (0.506) 1.8716 (1.208)
Psychotic symptoms (%) 33.8 0.4662 (0.212)* 0.6582 (0.408)
Charlson comorbidity Index 1.5 (1.1) 0.8575 (0.193) 0.7211 (0.230)
Female (%) 61.2 0.4398 (0.253) 0.3628 (0.252)
Baseline age 76.3 (8.1) 0.8647 (0.036)*** 1.0006 (0.047)
Live at home (%) 84.0 2.0245 (1.145) 6.817 (5.773)**
Site (reference group=Columbia)
Johns Hopkins (%) 25.4 2.1374 (1.568) 0.712 (0.678)
Massachusetts General (%) 28.4 0.4192 (0.272) 1.8689 (1.470)
Year of entry into study 2001 (1.9) 1.0529 (0.163) 6.8229 (1.973)***
Interval — 1.2866 (0.202)* 5.2686 (1.828)***
Interval squared — 0.9835 (0.014) 0.9487 (0.023)**
AIC — 417.426 271.696
BIC — 482.58 336.85
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use memantine (OR=0.71, P<0.05), as were those with
better cognition (OR=0.81, P<0.001). Living at home was
significantly associated with higher likelihood of using
memantine (OR=6.82, P<0.01). Later entry year was
significantly associated with higher likelihood of using
memantine (OR=6.82, P<0.001). After controlling for
entry year, patients were more likely to use memantine over
time (OR=5.27, P<0.001), although the rate of increase
slowed over time (OR=0.95, P<0.01).
In a secondary analysis, we controlled for the effect of
concurrent use of memantine in the ChEIs equation.
Results showed that concurrent use of ChEIs did not have
a significant effect on memantine use. The effect of
concurrent use of ChEIs in the equation estimating
memantine use also was statistically insignificant.
Unadjusted Results on Patterns of Other
Medications Use Over Time
On average, patients reported 4.3 prescription medica-
tions at each interval. These medications belonged to 2.1
drug categories at baseline, increasing to 2.6 in year 6
(P=0.004). We computed the percentage of patients who
were on medications by drug category at each visit (Fig. 2).
For all assessment intervals, the most frequently used
medications included antihypertensives (overall average
use rate=53.0%), antiplatelets (overall average use rate=
35.2%), antidepressants (overall average use rate=37.8%),
and medications for dyslipidemia (overall average use
rate=31.3%). Tests for trend over time in these 4 drug
categories using random effects logistic regressions show
increases in the use rates of antihypertensives and
antidepressants (both P<0.001) but not in medications
for dyslipidemia and antiplatelets.
Use rates for 2 additional categories of medications
changed substantially over time. Specifically, hormone use
steadily decreased from 19.4% at baseline to 5.4% in year
6, and antipsychotics use increased steadily from 3.5% at
baseline to 27.0% in year 6 (both P-values for trend over
time<0.001).
Other prescription medications were used less fre-
quently, with an average overall rate ranging from 7.0% for
anticoagulants and NSAIDs to 8.8% for antidiabetics.
With few exceptions, use rate of 5 categories of drugs (ie,
antihistamines, antiepileptics, Parkinson disease medica-
tions, stimulants, and antiemetic neuroleptics) was lower
than 5% at all assessment intervals.
Use of other prescription and OTC medications were
common. At each assessment interval, vitamins were the
most frequently used, although utilization rate decreased
from 79.1% at baseline to 64.9% in year 6 (P=0.002), use
of other prescription medications increased from 46.3% to
64.9% (P<0.001), and other OTC medications fluctuated
between 39.7% and 48.8% (P>0.05).
DISCUSSION
In this study, we prospectively followed a large cohort
of patients from early stages of AD and examined patterns
of ChEIs/memantine use over 6 years. This study extends
the literature in several fronts: (1) by examining patterns of
ChEIs/memantine use simultaneously, (2) by using multi-
variate analysis to explore the longitudinal relationship
between patient characteristics and ChEIs/memantine use
more rigorously, and (3) by describing patterns of
concomitant medication use more comprehensively.
Similar to recent studies that examined ChEIs use
among dementia patients,6–8,29,30 we found high rates of
ChEIs use, with donepezil being the most prevalent agent.
Over time, use patterns changed substantially. At baseline,
almost 80% of the patients used ChEIs only and none used
memantine; by year 6, almost half of the patients used both
ChEIs and memantine. These use patterns suggest adher-
ence to current practice guidelines of initiating a ChEIs in
milder stages of AD, followed by initiation of memantine in
moderate to severe stages of the disease. At each assessment
interval, however, approximately 20% of the patients were
not using either ChEIs or memantine. The reason for not
using any antidementia therapies should be examined in
future studies.
The relationship between ChEIs use and several demo-
graphic characteristics have been explored recently.6,30 In
this study, ChEI use was associated with younger age but
memantine use was not significantly associated with age.
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FIGURE 2. Use of other medications by category over time.
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with other samples. Similar to previous findings, this study
did not find any gender differences in ChEI use.
Effects of clinical characteristics on ChEIs/memantine
use have not been examined earlier. Results from our
multivariate analyses show that, consistent with current
practice guidelines, patients were more likely to use ChEIs
and memantine as disease progresses after controlling for
availability of the medications. Over and above the chro-
nological development of the disease, use of ChEIs also was
associated with better function and not having psychotic
symptoms. Our results also show that different clinical
characteristics are associated with ChEIs and memantine
use. In particular, memantine use was associated with better
function, poorer cognition, and patient living at home.
The relationships of both ChEIs/memantine use with
better function suggest that patients on these medications
receive a functional benefit that results in continued use.
Alternatively, physicians may perceive patients with higher
functioning as more suitable candidates for ChEIs and
memantine use. The association between poorer cognition
and memantine use suggests that physicians appropriately
use cognitive decline as a benchmark for increasing disease
severity and initiate memantine in accordance with practice
guidelines.
There may be several reasons for the significant
relationship between living at home and higher likelihood
of using memantine. On the healthcare demand side, it is
likely that compared with institutionalized patients, pa-
tients who live at home have caregivers and family members
who act as advocates for treatment. On the supply side,
professional caregivers for patients living in nursing homes
may be less concerned with patients’ impaired cognitive
status and more concerned with the treatment of their other
symptoms and conditions.
Findings from the analyses suggest high rates of con-
comitant medication usage in this sample of AD patients.
Notably, the reported use of antihypertensive agents,
antidepressants, and antipsychotics increased significantly
over time. The increase in antidepressant and antipsycho-
tics use suggests that the treatment of dementia symptoms
is not limited to ChEIs and memantine. Further analyses
looking at behavioral symptoms of AD and their associa-
tion with rates of antidepressant and antipsychotics use
may help characterize the spectrum of pharmacologic
treatment for dementia. Among the patients who used
antipsychotics, the vast majority (95%) used atypical
antipsychotics. On account of the small number of patients
who used typical antipsychotics, we combined these drugs
into one class and did not test the sensitivity of our results
separating typical and atypical antipsychotics.
There are several limitations to our study. First,
patients were selected from tertiary care university hospitals
and specialized AD centers and represent a nonrandom
sample of those affected by the disease in the population.
Patients in our sample also were predominantly white and
highly educated. Caution is needed in generalizing the
results of this study to patients of other ethnicities, patients
at lower education and income levels, and to community
AD patients. Second, because of the different approval
dates of medications, we controlled for year of study entry
and interval in the analyses. However, we were unable to
take into account the uptake curve of new pharmaceutical
agents onto the market or availability on specific formul-
aries. As such, the effect of availability may be under-
estimated for patients entering the study near the time of
FDA approval. In contrast, because patients were selected
from specialized AD centers, careful clinical diagnosis of
AD and evaluations permit more reliable and complete
data and more accurate coefficient estimates. Uptake of
new pharmaceutical agents by the physicians in these
specialized AD centers may be faster than in the general
community. The magnitude of the possible underestimation
of the effects on drug availability may be lessened. As the
patients were recruited at early disease stages and followed
for long periods of time, analyses are not compressed in
time and the cohort describes the full range of progression.
Longer-term effects are therefore more easily interpreted
and strengthen the confidence in our findings.
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